BDBM50296475 (3S,6S,9S,12S,15S)-3-amino-15-((2S,5S,8S,11S,14S,17S,18R)-17-((S)-2-((6S,9S,12S,15S,18S,21S,24S,27S)-1-amino-12-(3-amino-3-oxopropyl)-15-benzyl-6-carbamoyl-18,21,24-tris(carboxymethyl)-1-imino-9-isobutyl-8,11,14,17,20,23,26-heptaoxo-2,7,10,13,16,19,22,25-octaazaoctacosan-27-ylcarbamoyl)pyrrolidine-1-carbonyl)-11-sec-butyl-14-(4-hydroxybenzyl)-5-isobutyl-8,18-dimethyl-3,6,9,12,15-pentaoxo-4,7,10,13,16-pentaazaicosan-2-ylcarbamoyl)-9-(carboxymethyl)-6,12-diisobutyl-4,7,10,13-tetraoxo-5,8,11,14-tet::CHEMBL557344

SMILES: [#6]-[#6]-[#6@@H](-[#6])-[#6@H](-[#7]-[#6](=O)-[#6@H](-[#6])-[#7]-[#6](=O)-[#6@H](-[#6]-[#6](-[#6])-[#6])-[#7]-[#6](=O)-[#6@H](-[#6])-[#7]-[#6](=O)-[#6@H](-[#6]-[#6]-[#6](-[#8])=O)-[#7]-[#6](=O)-[#6@H](-[#6]-[#6](-[#6])-[#6])-[#7]-[#6](=O)-[#6@H](-[#6]-[#6](-[#8])=O)-[#7]-[#6](=O)-[#6@H](-[#6]-[#6](-[#6])-[#6])-[#7]-[#6](=O)-[#6@@H](-[#7])-[#6]-[#6](-[#8])=O)-[#6](=O)-[#7]-[#6@@H](-[#6]-c1ccc(-[#8])cc1)-[#6](=O)-[#7]-[#6@@H](-[#6@H](-[#6])-[#6]-[#6])-[#6](=O)-[#7]-1-[#6]-[#6]-[#6]-[#6@H]-1-[#6](=O)-[#7]-[#6@@H](-[#6])-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6](-[#8])=O)-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6](-[#8])=O)-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6](-[#8])=O)-[#6](=O)-[#7]-[#6@@H](-[#6]-c1ccccc1)-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6]-[#6](-[#7])=O)-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6](-[#6])-[#6])-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6]-[#6]\[#7]=[#6](\[#7])-[#7])-[#6](-[#7])=O

InChI Key: InChIKey=HRFCMZZHRXYCAS-LSIHJSPJSA-N

Data: 1 KI

Find this compound or compounds like it in BindingDB or PDB:

Substructure Similarity at least:  must be >=0.5 Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 1 hit for monomerid = 50296475   

Target/Host (Institution)	Ligand	Target/Host Links	Ligand Links	Trg + Lig Links	Ki nM	ΔG° kcal/mole	IC50 nM	Kd nM	EC50/IC50 nM	koff s-1	kon M-1s-1	pH	Temp °C
Hypoxia-inducible factor 1-alpha (Homo sapiens (Human))	BDBM50296475 ((3S,6S,9S,12S,15S)-3-amino-15-((2S,5S,8S,11S,14S,1...) Show SMILES [#6]-[#6]-[#6@@H](-[#6])-[#6@H](-[#7]-[#6](=O)-[#6@H](-[#6])-[#7]-[#6](=O)-[#6@H](-[#6]-[#6](-[#6])-[#6])-[#7]-[#6](=O)-[#6@H](-[#6])-[#7]-[#6](=O)-[#6@H](-[#6]-[#6]-[#6](-[#8])=O)-[#7]-[#6](=O)-[#6@H](-[#6]-[#6](-[#6])-[#6])-[#7]-[#6](=O)-[#6@H](-[#6]-[#6](-[#8])=O)-[#7]-[#6](=O)-[#6@H](-[#6]-[#6](-[#6])-[#6])-[#7]-[#6](=O)-[#6@@H](-[#7])-[#6]-[#6](-[#8])=O)-[#6](=O)-[#7]-[#6@@H](-[#6]-c1ccc(-[#8])cc1)-[#6](=O)-[#7]-[#6@@H](-[#6@H](-[#6])-[#6]-[#6])-[#6](=O)-[#7]-1-[#6]-[#6]-[#6]-[#6@H]-1-[#6](=O)-[#7]-[#6@@H](-[#6])-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6](-[#8])=O)-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6](-[#8])=O)-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6](-[#8])=O)-[#6](=O)-[#7]-[#6@@H](-[#6]-c1ccccc1)-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6]-[#6](-[#7])=O)-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6](-[#6])-[#6])-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6]-[#6]\[#7]=[#6](\[#7])-[#7])-[#6](-[#7])=O |r| Show InChI InChI=1S/C104H161N25O34/c1-16-52(11)82(127-87(147)56(15)112-91(151)64(37-48(3)4)117-85(145)54(13)111-89(149)63(32-34-76(132)133)116-93(153)67(40-51(9)10)121-97(157)71(45-79(138)139)123-94(154)65(38-49(5)6)119-88(148)60(105)43-77(134)135)102(162)126-69(42-58-27-29-59(130)30-28-58)100(160)128-83(53(12)17-2)103(163)129-36-22-26-74(129)101(161)113-55(14)86(146)118-70(44-78(136)137)96(156)124-73(47-81(142)143)99(159)125-72(46-80(140)141)98(158)122-68(41-57-23-19-18-20-24-57)95(155)115-62(31-33-75(106)131)90(150)120-66(39-50(7)8)92(152)114-61(84(107)144)25-21-35-110-104(108)109/h18-20,23-24,27-30,48-56,60-74,82-83,130H,16-17,21-22,25-26,31-47,105H2,1-15H3,(H2,106,131)(H2,107,144)(H,111,149)(H,112,151)(H,113,161)(H,114,152)(H,115,155)(H,116,153)(H,117,145)(H,118,146)(H,119,148)(H,120,150)(H,121,157)(H,122,158)(H,123,154)(H,124,156)(H,125,159)(H,126,162)(H,127,147)(H,128,160)(H,132,133)(H,134,135)(H,136,137)(H,138,139)(H,140,141)(H,142,143)(H4,108,109,110)/t52-,53-,54+,55+,56+,60+,61+,62+,63+,64+,65+,66+,67+,68+,69+,70+,71+,72+,73+,74+,82+,83+/m1/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	5.00E+4	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Institute of Science and Technology Curated by ChEMBL					Assay Description Inhibition of interaction between fluorescein-labeled proline hydroxylated human HIFalpha (556 to 575) and human VHL-human elongin B-human elongin C ...				Bioorg Med Chem Lett 19: 4403-5 (2009) Article DOI: 10.1016/j.bmcl.2009.05.083 BindingDB Entry DOI: 10.7270/Q2DJ5FP3
					More data for this Ligand-Target Pair